Compare RR & CTNM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
| Metric | RR | CTNM |
|---|---|---|
| Founded | 2016 | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | |
| Sector | | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 483.0M | 507.0M |
| IPO Year | 2023 | 2024 |
| Metric | RR | CTNM |
|---|---|---|
| Price | $1.92 | $12.73 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 2 | 4 |
| Target Price | $4.00 | ★ $19.00 |
| AVG Volume (30 Days) | ★ 6.7M | 322.8K |
| Earning Date | 05-13-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 0.46 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $5,045,000.00 | N/A |
| Revenue This Year | $75.68 | N/A |
| Revenue Next Year | $78.28 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 18.99 | N/A |
| 52 Week Low | $1.69 | $3.35 |
| 52 Week High | $7.43 | $16.33 |
| Indicator | RR | CTNM |
|---|---|---|
| Relative Strength Index (RSI) | 34.57 | 45.21 |
| Support Level | $1.81 | $11.54 |
| Resistance Level | $2.04 | $13.18 |
| Average True Range (ATR) | 0.14 | 0.99 |
| MACD | 0.02 | 0.07 |
| Stochastic Oscillator | 11.00 | 43.75 |
Richtech Robotics Inc is a robotics and artificial intelligence (AI) technology company focused on developing embodied AI systems that aims to improve the efficiency and productivity of businesses. The company trains proprietary artificial intelligence models on in-house data to operate robotic systems in the real world. It designs, engineers, manufactures, and deploys next generation embodied AI systems to serve a wide range of industries, including food service, retail, industrial manufacturing, automotive, healthcare, and hospitality. The company's offerings include Commercial Robotic Products, Industrial Robotic Products and Data Services. The company generated the majority of its revenue through product revenue (i.e. outright hardware sales).
Contineum Therapeutics Inc is a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies for NI&I indications with high unmet need. Its internally-discovered drug candidates, PIPE-791 and PIPE-307, PIPE-791, is a novel, brain penetrant, small molecule inhibitor of the LPA1R in development for IPF and PIPE-307, is a novel, small molecule selective inhibitor of the muscarinic type 1 M1R, in development for depression and RRMS.